FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to FDA Approval of Heparin Sodium Injection Continues to Demonstrate Mylan's Deep Expertise in Developing Complex Products
Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581       

Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581